Advertisement

best practice onkologie

, Volume 14, Issue 4, pp 142–151 | Cite as

Spätfolgen nach allogener Stammzelltransplantation

  • P. G. HemmatiEmail author
CME-Topic
  • 53 Downloads

Zusammenfassung

Gesundheitsrelevante Ereignisse, die mehr als 6 Monate nach allogener hämatopoetischer Stammzelltransplantation (alloHSZT) bestehen, werden als Spätfolgen bezeichnet und haben erheblichen Einfluss auf die Langzeitmorbidität und -letalität sowie die Lebensqualität der Patienten. Spätfolgen sind sehr heterogen hinsichtlich ihrer Ausprägung und ihres Schweregrads und werden in maligne und nichtmaligne Spätfolgen unterteilt. Ein besonderer Stellenwert kommt der Transplantat-gegen-Wirt-Reaktion und ihren Folgen zu. Die Überwachung der Spätfolgen erfordert eine lebenslange Nachsorge durch ein multidisziplinäres Team, welches eng mit niedergelassenen Hämatologen/Onkologen, Hausärzten und anderen Fachdisziplinen kooperiert. Strukturierte Nachsorgeprogramme sind essenziell, um Langzeitfolgen nach alloHSZT zu vermeiden bzw. frühzeitig zu erkennen und zu behandeln. Diese müssen durch Impfungen, Krebsvorsorgeuntersuchungen und weitere Maßnahmen zur Gesundheitsvorsorge ergänzt werden.

Schlüsselwörter

Transplantat-gegen-Wirt-Krankheit Transplantat-gegen-Wirt-Reaktion Transplantationsimmunologie Lebensqualität Impfung 

Late effects after allogeneic stem cell transplantation

Abstract

All health-related conditions that manifest more than 6 months after allogeneic hematopoietic stem cell transplantation (alloHSCT) are designated late effects. Late effects have a profound influence on long-term morbidity and mortality and also broadly affect the patients’ quality of life. Late effects are highly heterogeneous with regards to clinical characteristics and severity and are subdivided into malignant and non-malignant conditions. In particular, the development of graft-versus-host disease (GvHD) has a unique impact. Life-long surveillance and treatment of late effects requires a multidisciplinary team, which closely collaborates with hematologists/oncologists, primary care physicians, and other health care professionals. Structured follow-up programs are essential to diagnose and treat late effects as early as possible. They should be complemented by vaccinations, cancer prevention measures, and other health protection activities.

Keywords

Graft-versus-host disease Graft-versus-host reaction Transplantation immunology Quality of life Vaccination 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

P.G. Hemmati gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Passweg JR, Baldomero H, Bader P et al (2016) Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 51:786–792CrossRefGoogle Scholar
  2. 2.
    Hilgendorf I, Greinix H, Halter JP et al (2015) Long-term follow-up after allogeneic stem cell transplantation. Dtsch Arztebl Int 112:51–58PubMedPubMedCentralGoogle Scholar
  3. 3.
    Majhail NS (2017) Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 10:220–227CrossRefGoogle Scholar
  4. 4.
    Majhail NS, Tao L, Bredeson C et al (2013) Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant 19:1498–1501CrossRefGoogle Scholar
  5. 5.
    Hashmi S, Carpenter P, Khera N et al (2015) Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. Biol Blood Marrow Transplant 21:225–232CrossRefGoogle Scholar
  6. 6.
    Atsuta Y, Hirakawa A, Nakasone H et al (2016) Late mortality and causes of death among long-term survivors after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 22:1702–1709CrossRefGoogle Scholar
  7. 7.
    Bhatia S, Armenian SH, Landier W (2017) How I monitor long-term and late effects after blood or marrow transplantation. Blood 130:1302–1314CrossRefGoogle Scholar
  8. 8.
    Zeiser R, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377:2565–2579CrossRefGoogle Scholar
  9. 9.
    Socie G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124:374–384CrossRefGoogle Scholar
  10. 10.
    Wolff D, Bertz H, Greinix H et al (2011) The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. Dtsch Arztebl Int 108:732–740PubMedPubMedCentralGoogle Scholar
  11. 11.
    Carpenter PA, Englund JA (2016) How I vaccinate blood and marrow transplant recipients. Blood 127:2824–2832CrossRefGoogle Scholar
  12. 12.
    Maertens JA, Girmenia C, Bruggemann RJ et al (2018) European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother 73:3221–3230PubMedGoogle Scholar
  13. 13.
    Maertens J, Cesaro S, Maschmeyer G et al (2016) ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71:2397–2404CrossRefGoogle Scholar
  14. 14.
    Ullmann AJ, Schmidt-Hieber M, Bertz H et al (2016) Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 95:1435–1455CrossRefGoogle Scholar
  15. 15.
    Marty FM, Ljungman P, Chemaly RF et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433–2444CrossRefGoogle Scholar
  16. 16.
    Tuncer HH, Rana N, Milani C et al (2012) Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol 18:1851–1860CrossRefGoogle Scholar
  17. 17.
    Trottier BJ, Burns LJ, Defor TE et al (2013) Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood 122:1678–1684CrossRefGoogle Scholar
  18. 18.
    Jagus D, Lis K, Niemczyk L et al (2018) Kidney dysfunction after hematopoietic cell transplantation-Etiology, management, and perspectives. Hematol Oncol Stem Cell Ther 11:195–205CrossRefGoogle Scholar
  19. 19.
    Strong Rodrigues K, Oliveira-Ribeiro C, De Abreu Fiuza Gomes S et al (2018) Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 19:33–50CrossRefGoogle Scholar
  20. 20.
    Dyer G, Brice L, Schifter M et al (2018) Oral health and dental morbidity in long-term allogeneic blood and marrow transplant survivors in Australia. Aust Dent J.  https://doi.org/10.1111/adj.12627 CrossRefPubMedGoogle Scholar
  21. 21.
    Diab M, Zazadityafawi J, Soubani AO (2016) Major pulmonary complications after hematopoietic stem cell transplant. Exp Clin Transplant 14:259–270PubMedGoogle Scholar
  22. 22.
    Williams KM (2017) How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood 129:448–455CrossRefGoogle Scholar
  23. 23.
    Maffini E, Festuccia M, Brunello L et al (2017) Neurologic complications after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 23:388–397CrossRefGoogle Scholar
  24. 24.
    Chaudhary RK, Dhakal P, Aryal A et al (2017) Central nervous system complications after allogeneic hematopoietic stem cell transplantation. Future Oncol 13:2297–2312CrossRefGoogle Scholar
  25. 25.
    Kendler DL, Body JJ, Brandi ML et al (2018) Bone management in hematologic stem cell transplant recipients. Osteoporos Int 29:2597–2610CrossRefGoogle Scholar
  26. 26.
    Chow EJ, Wong K, Lee SJ et al (2014) Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:794–800CrossRefGoogle Scholar
  27. 27.
    Tichelli A, Passweg J, Wojcik D et al (2008) Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 93:1203–1210CrossRefGoogle Scholar
  28. 28.
    Majhail NS, Challa TR, Mulrooney DA et al (2009) Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 15:1100–1107CrossRefGoogle Scholar
  29. 29.
    Rizzo JD, Curtis RE, Socie G et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood 113:1175–1183CrossRefGoogle Scholar
  30. 30.
    Curtis RE, Metayer C, Rizzo JD et al (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105:3802–3811CrossRefGoogle Scholar
  31. 31.
    Majhail NS (2011) Secondary cancers following allogeneic haematopoietic cell transplantation in adults. Br J Haematol 154:301–310CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Hämatologie, Onkologie und PalliativmedizinKlinikum Ernst von BergmannPotsdamDeutschland

Personalised recommendations